Medicine and Dentistry
Nodular Melanoma
82%
Brain Metastasis
71%
Cancer Registry
71%
Skin Cancer
71%
Metastatic Melanoma
71%
Vemurafenib
71%
Trametinib
71%
Cobimetinib
71%
Diagnosis
47%
Diagnostic Accuracy
47%
CTLA-4
43%
Overall Survival
32%
Differential Diagnosis
23%
Clinician
23%
Cancer Classification
23%
Cancer Staging
21%
Metastasis Free Survival
21%
Progression Free Survival
16%
Immune Checkpoint Inhibitor
16%
Protein Kinases
14%
Fever
14%
Ipilimumab
12%
Electrocorticography
10%
Prognostic Factor
10%
Lactate Dehydrogenase
10%
Targeted Therapy
5%
Multivariate Analysis
5%
Systemic Therapy
5%
Proportional Hazards Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Metastasis
100%
Skin Cancer
71%
Cancer Registry
71%
Metastatic Melanoma
71%
Vemurafenib
71%
Cobimetinib
71%
Dabrafenib
71%
Cytotoxic T Lymphocyte Antigen 4
43%
Overall Survival
32%
Ipilimumab
23%
Metastasis Free Survival
21%
Cancer Staging
21%
Immune Checkpoint Inhibitor
16%
Progression Free Survival
16%
B Raf Kinase
14%
Protein Kinases
14%
Melanoma
10%
Lactate Dehydrogenase
10%
